This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (38)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Viral Infections  • Randomized Controlled Trial  • Liver/ Biliary Tract/ Pancreatic Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Seng Gee Lim, MD; Tay Meng Ng, MD; Nelson Kung, MD; Zahary Krastev, MD, PhD; Miroslava Volfova, MD, PhD; Petr Husa, MD, PhD; Samuel S. Lee, MD; Sing Chan, MD; Mitchell L. Shiffman, MD; Mary Kay Washington, MD, PhD; Amy Rigney, MEd; Jane Anderson, PhD; Elsa Mondou, MD; Andrea Snow, BS; Jeff Sorbel, MS; Richard Guan, MD; Franck Rousseau, MD; for the Emtricitabine FTCB-301 Study Group

Arch Intern Med. 2006;166:49-56.

Background  Emtricitabine is a nucleoside analogue approved for treatment of human immunodeficiency virus 1 with clinical activity against hepatitis B virus (HBV).

Methods  To compare the safety and efficacy of emtricitabine with placebo in patients with HBV, we conducted a randomized (2:1), double-blind study at 34 sites in North America, Asia, and Europe that enrolled adults between November 2000 and July 2002 who had chronic HBV infection but had never been exposed to nucleoside or nucleotide treatment. Each patient received either 200 mg of emtricitabine (n = 167) or placebo (n = 81) once daily for 48 weeks and underwent a pretreatment and end-of-treatment liver biopsy. Histologic improvement was defined as a 2-point reduction in Knodell necroinflammatory score with no worsening in fibrosis.

Results  At the end of treatment, 103 (62%) of 167 patients receiving active treatment had improved liver histologic findings vs 20 (25%) of 81 receiving placebo (P<.001), with significance demonstrated in subgroups positive (P<.001) and negative (P = .002) for hepatitis Be (HBe) antigen. Serum HBV DNA readings showed less than 400 copies/mL in 91 (54%) of 167 patients in the emtricitabine group vs 2 (2%) of 81 in the placebo group (P<.001); alanine aminotransferase levels were normal in 65% (109/167) vs 25% (20/81), respectively (P<.001). At week 48, 20 (13%) of 159 patients in the emtricitabine group with HBV DNA measured at the end of treatment had detectable virus with resistance mutations (95% confidence interval, 8%-18%). The rate of seroconversion to anti-HBe (12%) and HBe antigen loss were not different between arms. The safety profile of emtricitabine during treatment was similar to that of placebo. Posttreatment exacerbation of HBV infection developed in 23% of emtricitabine-treated patients.

Conclusion  In patients with chronic HBV, both positive and negative for HBe antigen, 48 weeks of emtricitabine treatment resulted in significant histologic, virologic, and biochemical improvement.

Author Affiliations: National University Hospital (Dr Lim), Changi General Hospital (Dr Ng), and Mount Elizabeth Medical Center (Dr Guan), Singapore; United Christian Hospital, Kowloon, Hong Kong Special Administrative Region, China (Dr Kung); University Hospital "St Ivan Rilsky," Sofia, Bulgaria (Dr Krastev); University Hospital Hradec Kralove (Dr Volfova) and University Hospital Brno (Dr Husa), Brno, Czech Republic; University of Calgary, Calgary, Alberta (Dr Lee); New York Hospital at Queens, Flushing, NY (Dr Chan); Virginia Commonwealth University Medical Center, Richmond, Va (Dr Shiffman); Vanderbilt University Medical Center, Nashville, Tenn (Dr Washington); and Gilead Sciences Inc, Durham, NC (Drs Anderson, Mondou, and Rousseau, Mss Rigney and Snow, and Mr Sorbel).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED ARTICLE

Treatment of Hepatitis B: Who, When, and How?
Stephen N. Wong and Anna S. F. Lok
Arch Intern Med. 2006;166(1):9-12.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Antiviral Therapy for Adults With Chronic Hepatitis B: A Systematic Review for a National Institutes of Health Consensus Development Conference
Shamliyan et al.
ANN INTERN MED 2009;150:111-124.
ABSTRACT | FULL TEXT  

Hepatitis B Virus Infection
Dienstag
NEJM 2008;359:1486-1500.
FULL TEXT  

Current treatment of hepatitis B
Dusheiko and Antonakopoulos
Gut 2008;57:105-124.
FULL TEXT  

Molecular Testing in the Diagnosis and Management of Chronic Hepatitis B
Valsamakis
Clin. Microbiol. Rev. 2007;20:426-439.
ABSTRACT | FULL TEXT  

Preexposure prophylaxis for HIV: unproven promise and potential pitfalls.
Liu et al.
JAMA 2006;296:863-865.
FULL TEXT  

Treatment of Chronic Hepatitis B with Emtricitabine
JWatch General 2006;2006:2-2.
FULL TEXT  

Treatment of Hepatitis B: Who, When, and How?
Wong and Lok
Arch Intern Med 2006;166:9-12.
FULL TEXT